Astec LifeSciences Ltd Stock Price Today (NSE: ASTEC)

Astec LifeSciences Ltd

787.90+49.65 (+6.73%)
Market Closed

Fundamental Score

...

Astec LifeSciences Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Astec LifeSciences Ltd share price today is 787.90, up +6.73% on NSE/BSE as of 18 June 2026. Astec LifeSciences Ltd (ASTEC) is a Small-cap company in the Pesticides & Agrochemicals sector with a market capitalisation of 1.82K (Cr). The 52-week high for ASTEC share price is 998.40 and the 52-week low is 513.40. The company has a Return on Equity (ROE) of -45.29% and a debt-to-equity ratio of 0.89.

Astec LifeSciences Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
797.00
Low
647.95
Volume
1.7L
Change
+1.51%

Astec LifeSciences Ltd share price chart: 1.51% return over the past month. 52-week high ₹998.40, 52-week low ₹513.40.

Astec LifeSciences Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
727.20822.75722.60787.903.66L (Cr)
769.70773.00732.50738.2538.80K (Cr)
763.50850.00755.65770.955.86L (Cr)
749.00785.00743.55761.2577.65K (Cr)
752.90769.80742.30746.9536.62K (Cr)
775.00775.35750.00752.9037.11K (Cr)
742.30788.15723.90771.801.20L (Cr)
758.00758.95731.00736.6541.58K (Cr)
737.95778.65724.90751.551.17L (Cr)
748.00761.85723.00738.751.97L (Cr)

Astec LifeSciences Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
769.70822.75722.60787.90+2.36%
694.70850.00647.95770.95+10.98%
564.00769.70534.00694.70+23.17%
616.00649.00513.40540.60-12.24%
571.00682.00562.40623.70+9.23%
715.00729.00557.00575.00-19.58%
826.05867.80697.10705.00-14.65%
669.00941.75607.05837.90+25.25%
796.65847.00655.00660.05-17.15%
883.60905.30788.50804.70-8.93%
902.00933.85780.20872.70-3.25%
918.23978.30833.60906.30-1.30%

AI Research Briefing

Powered by Gemini · 2026-04-09

Small-cap agrochem turnaround story hinges on CDMO growth, but past losses and high debt are major concerns.

Research Confidence
6.0/10Moderate
DEBT TRAP TURNAROUNDConsolidation after recovery from 52-week low. 1M: 24.19%, 3M: -4.54% [cite: Brief]Nonex P/E vs Industry P/E of 29.36x [cite: Brief] - difficult to value given losses.

WHAT'S HAPPENING NOW (last 2-4 weeks)

Astec LifeSciences experienced a volatile period. On March 23, 2026, the stock declined to a 52-week low of However, it showed signs of stabilization with a modest recovery on March 24, 2026, closing at For the week ending March 27, 2026, the stock gained 4.07%, closing at , outperforming the Sensex.

CORE STORY (THE REAL GAME)

Astec is a play on the Indian agrochemical industry, specifically riding on contract manufacturing and exports. The market narrative is a turnaround story, betting on improved CDMO offtake and new herbicide manufacturing to diversify from triazole fungicides.

Why Now
  • Q3 FY26 showed strong revenue growth driven by CDMO and enterprise volumes
  • EBITDA turned positive in Q3 FY26 at ₹4.8 crore
  • Stock has recovered from 52-week low, showing some resilience
Potential Catalysts
  • Significant new order wins in the CDMO segment
  • Successful diversification into new product lines like herbicides
  • Improvement in operating margins and reduction in debt
Key Risks
  • Small-cap: liquidity risk
  • History of operating losses and negative free cash flow
  • High debt-to-equity ratio and insufficient earnings to cover interest expenses
Institutional Activity

Promoter holding increased by 1.55% [cite: Brief]. FII and DII holdings decreased [cite: Brief].

Macro Context

Agrochemicals market in India is projected to grow, but susceptible to monsoon vagaries.

Cash Flow Quality

No - Free Cash Flow 5Y: ₹-381.94 Cr [cite: Brief]

3–6 Month Outlook

Monitor CDMO growth and margin improvement over the next 2 quarters. Successful diversification into new products is key.

Primary Thesis Risk

Failure to turnaround operations and manage debt will lead to collapse.

For educational purposes only. Not investment advice. Consult a SEBI-registered advisor before investing.

Returns & Performance

Poor

Return on Equity (ROE)

-45.29%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-12.86%

Returns generated on total capital deployed

Average

Oper. Profit Margin (5Y Avg)

10.02%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Astec LifeSciences Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

29.36x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

72.42%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

4.01%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

36.64%

Net profit growth vs same quarter last year

Poor

Revenue Growth (Quarterly YoY)

-25.20%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-6.11%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Poor

Debt to Equity Ratio

0.89x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-1.47x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-381.94 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Astec LifeSciences Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of ASTEC across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Robust Profit Growth (36.64%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Balanced Promoter Holding (72.42%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

8 factors identified

Below-Average Return on Equity (-45.29%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-12.86%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Revenue Contraction (-25.20%)

Observation: Sales decline may indicate market challenges or competitive pressures.

Analysis: Negative revenue growth requires analysis of market conditions.

Limited Growth History (-6.11% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-1.47x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-381.94 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

Limited Institutional Interest (FII+DII: 4.01%)

Observation: Low institutional participation may affect liquidity.

Analysis: Limited institutional interest may indicate size constraints or visibility issues.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Astec LifeSciences Ltd vs Pesticides & Agrochemicals Peers

Peer Comparison - Pesticides & Agrochemicals

Compare Astec LifeSciences Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
17/100
788
₹1818.40
-45.29%
Poor
-12.86%
Poor
0.9
Good
-6.11%
Poor
0.00%
UPL Ltd...
UPL512070
29.8/100
656
₹63303.75
26.7
Average
3.29%
Poor
7.66%
Poor
0.9
Good
-16.10%
Poor
5.46%
Good
0.80%
63.8/100
2847
₹51402.12
34.0
Average
17.61%
Good
22.86%
Excellent
0.0
Excellent
29.53%
Excellent
18.83%
Excellent
0.47%
51.9/100
496
₹23622.23
43.7
Average
18.81%
Good
25.14%
Excellent
0.0
Excellent
17.27%
Excellent
4.98%
Average
0.25%
46/100
4616
₹20761.67
34.1
Average
19.96%
Good
24.80%
Excellent
0.0
Excellent
-0.06%
Poor
8.68%
Good
2.71%
68.3/100
935
₹7868.22
17.4
Average
12.62%
Average
16.50%
Good
0.0
Excellent
8.25%
Good
16.62%
Excellent
1.03%
56.7/100
1180
₹5600.99
20.0
Average
21.95%
Excellent
28.29%
Excellent
0.0
Excellent
15.69%
Excellent
12.69%
Good
0.16%
28.4/100
251
₹5133.00
30.1
Average
6.65%
Poor
10.12%
Average
0.0
Excellent
-6.88%
Poor
3.41%
Average
0.95%
32.4/100
1489
₹4344.48
31.3
Average
11.09%
Average
14.33%
Average
0.1
Excellent
-6.27%
Poor
-0.71%
Poor
0.01%
0/100
161
₹3826.07
-25.75%
Poor
-7.80%
Poor
1.1
Average
4.00%
Average
0.00%
31.2/100
245
₹3163.13
259.5
Average
2.53%
Poor
5.19%
Poor
0.3
Excellent
22.42%
Excellent
12.39%
Good
0.06%

Astec LifeSciences Ltd PE Ratio History

Historical price-to-earnings ratio for ASTEC — last 5 years

YearEPS (₹)Price (₹)P/E Ratio
FY 202312.94₹1095.2584.6x
FY 202245.50₹1751.0038.5x

P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.

Astec LifeSciences Ltd Dividend History

Annual cash dividends paid by ASTEC — dividend yield N/A

Financial YearDividends Paid (₹ Cr)
FY 20242.94 Cr
FY 20232.94 Cr
FY 20222.94 Cr
FY 20212.94 Cr

Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.

Astec LifeSciences Ltd Quarterly Performance

Latest quarterly metrics for ASTEC — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

-25.20%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

36.64%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-6.11%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Astec LifeSciences Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for ASTEC — calculated from daily price history

58RSI 14
Neutral — RSI 58

Momentum is balanced — neither overbought nor oversold.

SMA 50
662
▲ Price above SMA 50 — Short-term bullish
SMA 200
710
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
220K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Astec LifeSciences Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Astec LifeSciences Ltd (ASTEC) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Astec LifeSciences Ltd

About ASTEC (Astec LifeSciences Ltd)

Astec LifeSciences Ltd is a pivotal player in the agrochemical sector, specializing in the meticulous creation of essential ingredients that underpin modern agriculture. The compan...y's expertise lies in synthesizing active ingredients for crop protection products, primarily focusing on triazole fungicides. These compounds are instrumental in safeguarding a wide spectrum of crops from fungal diseases, contributing to improved yields and reduced post-harvest losses. Astec meticulously engineers its products to meet the stringent demands of the agricultural industry, ensuring both efficacy and environmental responsibility. Through constant innovation and a commitment to sustainable practices, Astec LifeSciences strengthens its position as a reliable supplier for global crop protection companies. Beyond fungicides, Astec LifeSciences also produces a range of specialized chemical intermediates vital to the pharmaceutical industry. These intermediates serve as key building blocks for complex drug molecules, showcasing the company's versatile chemistry capabilities. This dual focus on agrochemicals and pharmaceutical intermediates positions Astec as a significant contributor to both food security and human health. The company invests significantly in research and development, constantly seeking to refine its processes and develop novel compounds that address emerging challenges in both agricultural and pharmaceutical sectors. Astec understands the importance of quality and precision in its manufacturing processes, assuring that its outputs adhere to the highest industry standards. Operating within India, Astec LifeSciences leverages its local expertise and infrastructure to serve a global clientele. The company strategically cultivates its strong relationships with both domestic and international clients. Astec's commitment to reliable supply chains, combined with a deep understanding of the agrochemical and pharmaceutical markets, makes it a trusted partner for organizations seeking high-quality chemical solutions. With its blend of scientific expertise, manufacturing proficiency, and a focus on responsible business practices, Astec LifeSciences contributes significantly to advancing agricultural productivity and pharmaceutical innovation.

Company Details

Symbol:ASTEC
Industry:Pesticides & Agrochemicals
Sector:Pesticides & Agrochemicals

Key Leadership

Mr. Burjis Nadir Godrej
MD & Additional Non-Executive Non- Independent Director
Ms. Mugdha Amol Khare
Chief Financial Officer
Mr. Arijit Mukherjee
Chief Operating Officer

Corporate Events

Recent
Ex-Dividend Date

ASTEC Share Price: Frequently Asked Questions

What is the current share price of Astec LifeSciences Ltd?

Astec LifeSciences Ltd (ASTEC) trades at ₹787.90 on NSE and BSE. Market cap ₹1.82K (Cr). Educational data only.

What is the P/E ratio of Astec LifeSciences Ltd?

Astec LifeSciences Ltd has a P/E of N/Ax vs industry average 29.36x.

What is the Bull Run score for Astec LifeSciences Ltd?

Astec LifeSciences Ltd has a Bull Run score of 17/100 based on 25+ financial parameters.

Does Astec LifeSciences Ltd pay dividends?

Astec LifeSciences Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Astec LifeSciences Ltd?

Astec LifeSciences Ltd has ROE of -45.29%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Astec LifeSciences Ltd?

Astec LifeSciences Ltd has debt-to-equity of 0.89.

Is Astec LifeSciences Ltd a good investment?

Bull Run gives Astec LifeSciences Ltd a score of 17/100. This is not investment advice — consult a SEBI-registered advisor.